

Curriculum Vitae

A.R.M. Ruhul Amin, B. Pharm, M. Pharm, Ph.D.
Assistant Professor of Pharmacology
Department of Pharmaceutical Sciences and Research
School of Pharmacy, Marshall University
1 John Marshall Drive, Huntington, WV, 25755
Tel # 1-304-696-7371 (O), 1-404-210-2102 (C)
E-mail: amina@marshall.edu

Summary

A highly motivated and dedicated individual with hands on experience within pharmaceutical sciences that includes analytical chemistry, medicinal chemistry, pharmaceutical manufacturing, quality control and quality assurance, biochemistry and molecular biology, physiology, and pharmacology with the ability to work in a multidisciplinary environment. Possess good communication, problem solving, analytical, interpersonal, time management and organizational skills.

Research Focus

My research focuses on understanding the mechanism of apoptosis and drug resistance and developing more effective and safer drugs or drug combinations for the treatment and prevention of cancers using natural and molecularly targeted compounds. My laboratory is also interested in understanding the mechanism of carcinogenesis and identifying biomarkers associated with carcinogenesis and drug response.

Education

- 2003 Ph.D. (Medical Science), Nagoya University School of Medicine, Nagoya, Japan.
Thesis Title: A role for SHPS-1/SIRP α 1 in IL-1 β - and TNF α -dependent signaling.
- 1991 M. Pharm. (Master of Pharmacy), University of Dhaka, Bangladesh.
Thesis Title: Studies on a *Penicillium* species.
- 1990 B. Pharm. (Bachelor of Pharmacy), University of Dhaka, Bangladesh.

Graduate/Postgraduate Trainings

- 08/2007-08/2009 Research Associate, Winship Cancer Institute of Emory University, GA.
Utilizing chemistry, biochemistry, pharmacology, biopharmaceutics, cellular and molecular biology knowledge to investigate the mechanism of drug actions.
- 05/2004-07/2007 Postdoctoral Fellow, Case Western Reserve University, OH. Cellular biology of human cancer cell lines using natural compounds to dissect the molecular basis of p53-dependent and independent pathway of programmed cell death/apoptosis.

- 10/1998-03/2003 Graduate (Ph.D.) student, Nagoya University School of Medicine. Study the molecular mechanism of tumor invasion and metastasis, particularly the role of microenvironments in regulating invasion.
- 07/1990-06/1992 M. Pharm. (Master of Pharmacy), Department of Pharmacy, University of Dhaka. Thesis title: Isolation and characterization of soil microorganisms and their bioactive metabolites.

Academic and Professional Appointments

- 1995- 1996 Production Officer, Beximco Pharmaceuticals Ltd. Bangladesh
- 1996- 1998 Lecturer, Department of Pharmacy, Rajshahi University, Bangladesh
- 2003- 2004 Assistant Professor, Department of Pharmacy, Rajshahi University, Bangladesh
- 2004 Associate Professor, Department of Pharmacy, Rajshahi University, Bangladesh
- 2004- 2005 Research Scholar, Department of Genetics, Case Western Reserve University, OH
- 2006- 2007 Research Associate, Department of Genetics, Case Western Reserve University, OH
- 2007- 2008 Senior Research Associate, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
- 2009-2011 Instructor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
- 2011- 2017 Assistant Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
- 2017- Assistant Professor, Department of Pharmaceutical Sciences and Research, School of Pharmacy, Marshall University, Huntington, WV
- 2018- Adjunct Assistant Professor, Department of Biomedical Sciences, School of Medicine, Marshall University, Huntington, WV

Teaching Experience

1. Formal Teaching:
 - a. Graduate Programs:
 - Marshall University**
 - Therapeutics IV: PHAR751 (Pathophysiology and Pharmacology of CNS diseases)
 - Therapeutics VI: PHAR761 (Pathophysiology and Pharmacology of Cancers, Blood disorders and Bone diseases)
 - Therapeutics III: PHAR671 (Pathophysiology and Pharmacology of Cardio, Renal and Pulmonary disorders): **Course coordinator**
 - Graduate Seminar (MSPS 542): **Course coordinator**
 - Emory University**
 - CB 555: Small group discussion (Transcriptional Regulation of Gene Expression)
 - CB 556: Small group discussion (Transcriptional Regulation of Gene Expression)
 - IBS 524 (Cancer Biology): Transmembrane Receptors, Cytokine Receptors, Receptor Tyrosine Kinase Signaling

Rajshahi University, Bangladesh

Bachelor of Pharmacy Program, Rajshahi University, Bangladesh: Pharmacology (Cardiovascular, Oncology), Microbiology, Pharmaceutics, Molecular Biology, Medicinal Chemistry, Biochemistry

Master of Pharmacy Program, Rajshahi University, Bangladesh: Pharmacology, Molecular Biology, Medicinal Chemistry

- b. Undergraduate Program (Emory University)
 - Bio 141: Foundation of Modern Biology I Lab
 - Bio 142: Foundation of Modern Biology II Lab

2. Supervisory Teaching:

a. Post-doctoral Fellows:

Abu Hasanat Md. Zulfikar, Ph. D., Marshall University
Abedul Haque, Ph. D., Emory University
A.S.M. Anisuzzaman, Ph. D., Emory University
Mohammad Aminur Rahman, Ph. D., Emory University
Sudeshna Goswami, Ph. D., Emory University

b. Students

Marshall University

Iniabashi Okon: Pharm. D. student
Breana Boirie: Pharm. D. student
Brian Butler: Pharm. D. student
Desmond Besong: Pharm. D. student
Nana Bosomtwe: M. D. student
Adeoluwa Adeluola, MSPS student

Emory University

Shanewaz Khan, Emory Undergraduate Program
Lekha Chilakamarri: Emory Undergraduate Program
Shayan Rakhit: Summer Scholar Research Program of Winship Cancer Institute
Michelle Lee: Summer Scholar Research Program of Winship Cancer Institute
Arusa Siddiqa: High School Intern for a full year

Rajshahi University

Helal Uddin Biswas: Co-supervisor of M. Pharm. Thesis
Proma Khandkar: Co-supervisor of M. Pharm. Thesis

Scholarship/Award/Fellowship

2020	Distinguished Researcher Award, Association of Pharmacy Professionals
2019	Best Team, Marshall University School of Pharmacy
2013	Rising Star, Department of Hematology and Medical Oncology, Emory University
2012	Robbins Scholar Award, Winship Cancer Institute
1998	Japanese Govt. Monbusho Scholarship
2002	Travel grants from the Department of Molecular Pathogenesis, Nagoya University

2003 Travel grants from the Department of Molecular Pathogenesis, Nagoya University

Committee Membership

Marshall University

2020- Faculty Senate, Marshall University
2020- Faculty Senate Executive Committee, Marshall University
2019-2020 Open Access Policy Ad Hoc Committee
2017-2018 Curriculum Committee, School of Pharmacy
2017-2019 Assessment Committee, School of Pharmacy
2018-Prsent Admission Committee, School of Pharmacy
2018-Present Admission Committee, MSPS, School of Pharmacy
2019 Selection Committee, Post-doc
2018 Selection Committee, Instructor Search
2018 Selection Committee, Assistant Professor Search
2018 Selection Committee, Laboratory Assistant Search
2018 Selection Committee, Chair Search

Emory University

2014-2017 Curriculum Committee, Cancer Biology Graduate Program
2014-2017 Qualifying Examination Committee, Cancer Biology Graduate Program

Editorial Board

2015-2018 *World Journal of Clinical Oncology*
2013-Present *PLoS One*
2014-Present *Frontiers in Cell and Developmental Biology*
2015-Present *Cancer Epidemiology*
2016-Present *Annals of Carcinogenesis*

Journal Reviewer

Cancer Research
Cancer Letters
Cancer
Molecular Cancer Therapeutics
Molecular Carciogenesis
Carcinogenesis
Cell Cycle
Oncotarget
Mutation Research
BMC Cancer
Cancer Research Frontiers
PLOS One
Toxicology and Applied Pharmacology

Agriculture
Phytotherapy Research
BMC Complementary and Alternative Medicine
Journal of Cell Science
FEBS Journal

Society Membership

American Association of College of Pharmacy
American Association of Cancer Research
Bangladeshi American Pharmacists' Association (Life Member)
Association of Pharmacy Professional
American Association of Bangladeshi Pharmaceutical Scientists

Invited Lectures

1. Mechanism of Resistance to Targeted Therapy in Head and Neck Cancer. Department of Clinical Oncology, MUSOM, February 12, 2020
2. Toward Personalized Treatment of Head and Neck Cancer: Current Status and Future Perspectives. Guest Speaker, Dhaka University Bangladesh, June 2016
3. Toward Personalized Cancer Treatment: Current Status and Future Perspectives. Guest Speaker, Northern University, Dhaka, Bangladesh, June 2016
4. Toward Personalized Therapy: Current Status and Future Perspectives. Keynote Speaker, State University of Bangladesh, June 2016
5. Co-targeting EGFR and PI3K in Head and Neck Cancer: Mechanisms of Synergy and Resistance. Third AABPS Convention, Philadelphia, PA. 2015
6. Key Note Speaker, Seminar on "Cancer Prevention: Future Perspective with Natural Compound". Southeast University, Dhaka, Bangladesh, 2014
7. 2014: Key Note Speaker, Seminar on "Cancer Prevention with Natural Compound". Daffodil University, Dhaka, Bangladesh, 2014
8. Key Note Speaker, Seminar on "Cancer Prevention: Past, Present and Future". State University of Bangladesh, 2014
9. Elkin Lecture Series, Winship Cancer Institute of Emory University, 2008
10. Role of Akt-Foxo1a signaling in synergistic growth inhibition of squamous cell carcinoma of the head and neck by EGFR tyrosine kinase inhibitor erlotinib and green tea polyphenol EGCG. NCI Translational Science Meeting, 2008
11. Targeting multiple signaling pathways with a combination of two dietary polyphenols, EGCG and luteolin: potential for chemoprevention of SCCHN. NCI Translational Science Meeting, 2009
12. Elkin Lecture Series, Winship Cancer Institute of Emory University, 2010
13. Biomarkers for Chemoprevention of Head and Neck Cancer with EGFR-TKI and Cox-2I. NCI Translational Science Meeting, 2011

Grant Supports

Active

1. Startup fund, Department of Pharmaceutical Sciences, School of Pharmacy, Marshall University

2. Faculty Research Support funding (No cost extension)

Title: Mechanism of synergism by the combination of EGCG and luteolin in head and neck cancer

3. WV INBRE Cancer Biology (PI: Amin)

Title: Genetic profiling of HNC cell lines resistant to apoptosis induced by EGFR and PI3K co-targeting

4. WV INBRE Center for Natural Products (PI: Amin)

Title: Microbial extracts for the treatment of tobacco-associated malignancies

5. WV INBRE Center for Natural Products (PI: Amin)

Title: Chemoprevention of head and neck cancer by the combination of EGCG and resveratrol

6. WV INBRE Cancer Biology (co-PI: Amin)

Title: Exploring the role of GPR68 in head and neck carcinogenesis and treatment

Pending

1. R15 (PI: Amin)

Title: Targeting Cell Survival Pathways for the Chemoprevention of Head and Neck Cancer

2. R15 (PI: Amin)

Title: Mechanism of Apoptosis Resistance to Targeted Therapy in Head and Neck Cancer

Completed

1. R03CA159369: 03/01/2012-2/28/2014 (PI: Amin)

Title: Mechanism of chemopreventive synergism from the combination of EGCG and Erlotinib

Funding Agency: NIH/NCI

Total Funding: \$100K (direct)

2. R03CA171663: 03/01/2013-02/28/2015 (PI: Amin)

Title: Targeting both intrinsic and extrinsic apoptosis by FLLL-12 in lung cancer

Funding agency: National Cancer Institute

Total Funding: \$100K (direct)

3. SPORE in Head and Neck, Career Development Award (PI: Amin)
Title: Chemoprevention of Squamous Cell Carcinoma of the Head and Neck by Dietary Polyphenols EGCG and Luteolin
Funding Agency: NIH
Total Funding: \$60K
4. Robbins Scholar Award (00023544): 03/01/2012-2/28/2014 (PI: Amin)
Title: Combination of natural compounds EGCG and luteolin for prevention of HNC
Funding Agency: Winship Cancer Institute
Total Funding: \$60K
5. School of Medicine and School of Pharmacy Collaborative Grant (Co-PI)
Title: Chemoprevention of lung cancer using combination of EGCG and luteolin

Publications

Research Articles

1. **Amin AR***, Wang D, Nannapaneni S, Lamichhane R, Chen ZG and Shin DM. Combination of resveratrol and green tea epigallocatechin gallate induces synergistic apoptosis and inhibits tumor growth in vivo in head and neck cancer models. *Oncology Reports* (Accepted).
*Corresponding author
2. Journigan VB, Feng Z, Rahman S, Wang Y, **Amin AR**, Heffner C, Bachtel N, Wang S, Gonzalez-Rodriguez S, Fernández-Carvajal A, Fernández-Ballester G, Hilton J, Van Horn W, Ferrer-Montiel A, Xie XQ, Rahman T. Structure-based design of novel biphenyl amide antagonists of human Transient Receptor Potential Cation Channel Subfamily M Member 8 channels (TRPM8) with potential implications in the treatment of sensory neuropathies. *ACS Chemical Neuroscience*, 2020; 11:268-290.
3. Anisuzzaman ASM, Haque A, Wang D, Rahman MA, Zhang C, Chen Z, Chen ZG, Shin DM and **Amin AR**. *In vitro* and *in vivo* synergistic anti-tumor activity of the combination of BKM120 and erlotinib in head and neck cancer: Mechanism of apoptosis and resistance. *Molecular Cancer Therapeutics*, 2017; 16:729-738.
4. Wang D, Qian G, Zhang H, Magliocca KR, Nannapaneni S, **Amin AR**, Rossi M, Patel M, El-Deiry M, Wadsworth JT, Chen Z, Khuri FR, Shin DM, Saba NF, Chen ZG. HER3 targeting sensitizes HNSCC to cetuximab by reducing HER3 activity and HER2/HER3 dimerization - evidence from cell line and patient derived xenograft models. *Clinical Cancer Research*, 2017; 23:677-686.
5. Wang D, Peng S, **Amin AR**, Rahman MA, Nannapaneni S, Liu Y, Shin DM, Saba NF, Eichler JF, Chen ZG. Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-Phenanthroline. *PLoS One*, 2016; 11:e0168450.
6. Anisuzzaman ASM, Haque A, Rahman MA, Wang D, Fuchs JR, Hurwitz S, Liu Y, Sica G, Khuri FR, Zhuo Chen ZG, Shin DM and **Amin AR**. Preclinical *in vitro*, *in vivo* and

- pharmacokinetic evaluations of FLLL12 for the prevention and treatment of head and neck cancers. *Cancer Prevention Research*, 2016; 9:63-73.
7. Haque A, Rahman MA, Fuchs JR, Chen ZG, Khuri FR, Shin DM and **Amin AR**. FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway. *Cancer Letters*, 2015; 363:166-75.
 8. Haque A*, Rahman MA, Chen ZG, Saba NF, Khuri FR, Shin DM and **Amin AR***. Combination of Erlotinib and EGCG Induces Apoptosis of Head and Neck Cancers through Post-transcriptional Regulation of Bim and Bcl-2. *Apoptosis*, 2015; 20:986-95. *These authors contributed equally to the manuscript.
 9. **Amin AR***, Haque A, Rahman MA, Chen ZG, Khuri FR and Shin DM. Curcumin induces apoptosis of upper aerodigestive tract cancer cells by targeting multiple pathways. *PLoS One*, 2015; 10:e0124218. *Corresponding author
 10. Jiang N, Wang D, Hu Z, Shin HJC, Qian G, Rahman MA, Zhang HZ, **Amin AR**, Nannapaneni S, Wang X, Chen Z, Garcia G, Macbeath G, Shin DM, Khuri FR, Ma J, Chen ZG and Saba NF. Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma. *Molecular Cancer Therapeutics*, 2014; 13:1826-36.
 11. Wang X, Beitler JJ, Wang H, Lee MJ, Huang W, Koenig L, Nannapaneni S, **Amin AR**, Bonner M, Shin HJC, Chen ZG, Arbiser JL and Shin DM. Honokiol Enhances Paclitaxel Efficacy in Multi-Drug Resistant Human Cancer Model through the Induction of Apoptosis. *PLoS One*. 2014; 9:e86369.
 12. Ng WL, Chen G, Wang M, Wang H, Story M, Shay JW, Zhang X, Wang J, **Amin AR**, Hu B, Cucinotta FA and Wang Y. OCT4 as a target of miR-34a stimulates p63 but inhibits p53 to promote human cell transformation. *Cell Death & Disease*, 2014; 5:e1024.
 13. Majumdar D, Jung KH, Zhang HZ, Nannapaneni S, Wang X, **Amin AR**, Chen Z, Chen ZG and Shin DM. Luteolin nanoparticle in chemoprevention- *in vitro* and *in vivo* anticancer activity. *Cancer Prevention Research*, 2014; 7:65-73.
 14. Rahman MA, **Amin AR**, Wang D, Koenig L, Nannapaneni S, Chen Z, Sica G, Deng X, Chen ZG and Shin DM. RRM2 Regulates Bcl-2 in Human Cancer: A Potential Target for Cancer Therapy. *Clinical Cancer Research*, 2013; 19:3416-28.
 15. Shin DM, Zhang HZ, Saba NF, Chen A, Nannapaneni N, **Amin AR**, Müller S, Lewis M, Sica G, Kono S, Brandes JC, Grist W, Beitler JJ, Thomas SM, Chen Z, Shin HJC, Grandis JR, Khuri FR and Chen ZG. Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies. *Clinical Cancer Research*, 2013; 19:1244-56.
 16. **Amin AR***, Thakur VS, Gupta K, Agarwal MK, Wald DN, Shin DM and Agarwal ML. N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: Potential for cancer therapy. *Oncogene*, 2013; 32:920-9. *Corresponding author
 17. Wang D, Muller S, **Amin AR**, Huang D, Su L, Rahman MA, Nannapaneni N, Koenig L, Chen Z, Tighiouart M, Shin DM, Hu Z and Chen ZG. Role of Integrin β 1 Metastasis of Head and Neck Squamous Cell Carcinoma. *Clinical Cancer Research*, 2012; 18:4589-99.

18. Rahman MA, **Amin AR**, Wang X, Zuckerman JE, Choi CH, Zhou B, Wang D, Nannapaneni N, Koenig L, Chen Z, Chen ZG, Yen Y, Davis ME and Shin DM. Systemic Delivery of siRNA-Nanoparticles Targeting RRM2 Suppresses Head and Neck Tumor Growth. *Journal of Controlled Release*, 2012; 159:384-92.
19. Thakur VS, **Amin AR**, Paul RK, Gupta K, Hastak K, Agarwal MK, Jackson MW, Wald DN, Mukhtar H and Agarwal ML. p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG. *Cancer Letters*, 2010; 296:225-32.
20. **Amin AR**, Wang D, Zhang HZ, Peng S, Shin HJC, Brandes JC, Tighiouart M, Khuri FR, Chen ZG and Shin DM. Enhanced Anti-tumor Activity by the Combination of the Natural Compounds (-)- Epigallocatechin-3-gallate and Luteolin: Potential role of p53. *Journal of Biological Chemistry*, 2010; 285:34557-65.
21. **Amin AR**, Thakur VS, Gupta K, Jackson MW, Harada H, Agarwal MK, Shin DM, Wald DN and Agarwal ML. Restoration of p53 functions protects cells from Concanavalin A-induced apoptosis. *Molecular Cancer Therapeutics*, 2010; 9:471-9.
22. **Amin AR**, Khuri FR, Chen ZG and Shin DM. Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and EGCG: the role of p53-dependent inhibition of nuclear factor-kappaB. *Cancer Prevention Research*, 2009; 2:538-45.
23. Hastak K, Paul RK, Agarwal MK, Thakur VS, **Amin AR**, Agarwal S, Sramkoski MR, Jacobberger JW, Jackson MW, Stark GR and Agarwal ML. DNA Synthesis from Unbalanced Nucleotide Pools Causes Limited DNA Damage that Triggers ATR-CHK1-Dependent p53 Activation. *Proceedings of National Academy of Science, U S A*, 2008; 105:6314-9.
24. **Amin AR**, Biswas MH, Senga T, Feng GS, Kannagi R, Agarwal ML and Hamaguchi M. A role for SHPS-1/SIRP α in concanavalin A-dependent production of MMP-9. *Genes to Cells*, 2007; 12:1023-1033.
25. **Amin AR**, Paul RK, Thakur VS and Agarwal ML. A Novel Role for p73 in the Regulation of Akt-Foxo1a-Bim Signaling and Apoptosis Induced by Concanavalin A. *Cancer Research*, 2007; 67:5617-5621.
26. **Amin AR**, Thakur VS, Paul RK, Feng GS, Mukhtar H and Agarwal ML. SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53-target genes induced by the green tea polyphenol EGCG. *Proceedings of National Academy of Science, U S A*, 2007; 104:5419-5424.
27. Agarwal MK*, **Amin AR*** and Munna L Agarwal ML. DNA replication licensing factor (MCM5) rescues p53-mediated growth arrest. *Cancer Research*, 2007; 67:116-121. *These authors contributed equally.
28. Biswas MH, Hasegawa H, Rahman MA, Huang P, Mon NN, **Amin AR**, Senga T, Kannagi R and Hamaguchi M. SHP-2-Erk signaling regulates Concanavalin A-dependent production of TIMP-2. *Biochemical Biophysical Research Communication*, 2006; 348:1145-9.
29. **Amin AR**, Jabbar A and Rashid MA. Antibacterial and cytotoxic activities of the metabolites isolated from a *Penicillium* strain. *Pakistan Journal of Biological Sciences*, 2003; 6:1365-1367.

30. **Amin AR**, Oo ML, Senga T, Suzuki N, Feng GS and Hamaguchi M. SHP-2 regulates Concanavalin A-dependent secretion and activation of MMP-2 via the Erk and p38 pathways. *Cancer Research*, 2003; 63:6334-9.
31. **Amin AR**, Senga T, Oo ML, Thant AA and Michinari Hamaguchi M. Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1 β : a role for the dual signaling pathways, Akt and Erk. *Genes to Cells*, 2003; 8:515-23.
32. Oo ML, Senga T, That AA, **Amin AR**, Huang P, Mon NN and Hamaguchi M. Cysteine residues in the C-terminal lobe of Src: their role in the suppression of the Src kinase. *Oncogene*, 2003; 22:1411-7.
33. **Amin AR**, Ichigotani Y, Oo ML, Biswas MH, Yuan H, Huang P, Mon NN and Hamaguchi M. The PLC-PKC cascade is required for IL-1 β -dependent Erk and Akt activation: their role in proliferation. *International Journal of Oncology*, 2003; 22:1727-32.
34. **Amin AR**, Machida K, Oshima K, Oo ML, Thant AA, Senga T, Matsuda S, Akhand AA, Maeda A, Kurosaki T and Hamaguchi M. A role for SHPS-1/SIRP α 1 in IL-1 β - and TNF α -dependent signaling. *Oncogene*, 2002; 21:8871-8.
35. Biswas MH, **Amin AR**, Bhuiyan MS, Rashid MA, Ahmed M and Islam MA. *In vitro* antibacterial screening of the metabolite of a *Monocillium* species isolated from a soil sample of Bangladesh. *The Sciences*, 2001; 1:25-27.
36. Thant AA, Nawa A, Kikkawa F, Ichigotani Y, Zhang Y, Sein TT, **Amin AR** and Hamaguchi M. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. *Clinical and Experimental Metastasis*, 2001; 18:423-8.
37. Sein TT, Thant AA, Hiraiwa Y, **Amin AR**, Shohara Y, Liu Y, Matsuda S, Yamamoto T and Hamaguchi M. A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and -9. *Oncogene*, 2000; 19:5539-42.
38. Biswas MH, **Amin AR**, Islam MA, Hasan CM, Gustafson KR, Boyd MR, Pannel LK and Rashid MA. Monocillinols A and B, novel fungal metabolites from a *Monocillium* sp. *Tetrahedron Letters*, 2000; 41:7177-80.
39. **Amin AR** and Jabbar A. Toxicological studies of two antibacterial metabolites isolated from a *Penicillium* strain on Long Evan's rats. *Journal of Bio-Science*, 1997; 5:229-34.
40. Islam MA, Khondhkar P, **Amin AR** and Rahman MM. Sub-acute toxicity of an antimicrobial metabolite isolated from a *Monocillium* species on Long Evan's rats. *Journal of Bio-Science*, 1997; 5:277-84.
41. Biswas MH, Islam MA and **Amin AR**. Brine shrimp lethality bioassay of the metabolites of a *Monocillium* species. *Journal of Bio-Science*, 1998; 6:129-32.

Review Articles

1. Block KI, Gyllenhaal C, Lowe L, **Amin AR**, *et al.* A broad-spectrum integrative design for cancer prevention and therapy. *Seminars in Cancer Biology*, 2015; 35 Suppl:S276-304.

2. **Amin AR**, Karpowicz PA, Carey TE, Jack Arbiser JL, *et al.*, Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. *Seminars in Cancer Biology*, 2015; 35 Suppl:S55-77.
3. Park W, **Amin AR**, Chen ZG and Shin DM. New perspectives of curcumin in cancer prevention. *Cancer Prevention Research*, 2013; 6:387-400.
4. Brandes JC, **Amin AR**, Khuri FR and Shin DM. Prevention of Lung Cancer: Future Perspective with Natural Compounds. *Tuberculosis and Respiratory Diseases*, 2010; 69:1-15.
5. Rahman MA, **Amin AR** and Shin DM. Chemopreventive potential of natural compounds in head and neck cancer. *Nutrition and Cancer*, 2010; 62:1-15.
6. Gullett NP, **Amin AR**, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, Aggarwal BB, Surh YJ and Kucuk O. Cancer Prevention with Natural Compounds. *Seminars in Oncology*, 2010; 37:258-281.
7. Kim J, **Amin AR** and Shin DM. Chemoprevention of Head and Neck Cancer with Green Tea Polyphenols. *Cancer Prevention Research*, 2010; 3:900-909.
8. **Amin AR**, Kucuk O, Khuri FR and Shin DM. Perspectives for Cancer Prevention with Natural Compounds. *Journal of Clinical Oncology*, 2009; 27:2712-25.
9. Osima K, **Amin AR**, Suzuki A, Hamaguchi M and Matsuda S. SHPS-1, a multifunctional transmembrane glycoprotein. *FEBS Letters*, 2002; 519:1-7.

Book Chapters

1. **Amin AR**, Hongzheng Zhang HZ and Shin DM. Molecular aspects of cancer prevention by green tea: an overview. *Tea in Health and Disease Prevention*, 1e Chapter 65. Elsevier.
2. Szollosi DE, Kinney SRM, Amin AR and Chumbow N. Pharmacology of Immunotherapeutic Drugs. Chapter 10: Cancer Immunotherapy, 2019, 321-351.

Abstract Presentations

1. Anisuzzaman AS, Haque A, Chen ZG, Shin DM and **Amin AR**. Src-Met signaling confers apoptosis resistance to EGFR and PI3K co-targeting independently of AKT and ERK pathway activation in head and neck cancer. AACR Annual Meeting, 2020
2. Bosomtwe NA and **Amin AR**. In vitro antitumor activity of natural extracts on head and neck cancer cells. MU Research Day, 2020
3. Journigan VB, Feng Z, Rahman S, Wang Y, **Amin AR**, Heffner CE, Bachtel N, Wang S, Gonzalez-Rodriguez S, Fernández-Carvajal A, Fernández-Ballester G, Hilton JK, Van Horn WD, Ferrer-Montiel A. Structure-based design of novel biphenyl amide antagonists of human Transient Receptor Potential Cation Channel Subfamily M Member 8 channels (TRPM8). ACS-MEDI Young Investigator Symposium, 2020
4. Anisuzzaman AS, Haque A, Butler B and **Amin AR**. A natural inhibitor of c-Met that sensitizes head and neck cancer cells resistant to EGFR and PI3K co-targeting. AACR Annual Meeting, 2019
5. Hossain MF, Sarder S, Benmerzouga I, **Amin AR** and Khan MOF. Tetraazamacrocyclic Quinoline derivatives as potential drug leads for lung cancer therapy. American Association for Pharmaceutical Sciences Annual Meeting, 2018.
6. Anisuzzaman ASM, Siddique AB, Fuchs JR and **Amin AR**. FLLL12 is a small molecule

- inhibitor of JAK2 that inhibits JAK-STAT3 pathway in head and neck cancer. AACR Annual Meeting, 2018
7. Hossain MF, Sarder S, Chowdhury S, Okon IA, Benmerzouga I, **Amin AR** and Khan MOF. Tetraazamacrocyclic Quinoline derivatives as potential drug leads for lung cancer therapy. Marshall Research Day, 2018
 8. Anisuzzaman ASM, Haque A, Chen ZG, Shin DM and **Amin AR**. Src-Met Signaling Confers Apoptosis Resistance to the Combination of BKM120 and Erlotinib in Head and Neck Cancer. AACR Annual Meeting, 2017
 9. Anisuzzaman ASM, Haque A, Chen ZG, Shin DM and **Amin AR**. Combination of BKM120 and erlotinib in squamous cell carcinoma of the head and neck: Mechanism of in vitro and in vivo synergy. AACR Annual Meeting, 2016.
 10. Haque A, Rahman MA, Fuchs JR, Chen ZG, Khuri FR, Shin DM and **Amin AR**. Potent curcumin analog FLLL12 induces apoptosis in lung cancer cells through death receptor-5-dependent pathway. AACR Annual Meeting, 2015.
 11. Rahman MA, **Amin AR**, Zhang J, Nannapaneni N, Saba NF, Chen ZG and Shin DM. Targeting RRM2 by siRNA inhibits cellular invasion and represents a rational approach for inhibition of metastasis of head and neck and lung cancers. AACR Annual Meeting, 2015.
 12. **Amin AR**, Haque A, Rahman MA, Fuchs JR, Chen ZG and Shin DM. Potent curcumin analog FLLL-12 targets both intrinsic and extrinsic signaling pathways to induce apoptosis in lung cancers. AACR Annual Meeting, 2014.
 13. Haque A, Rahman MA, Chen ZG, Shin DM and **Amin AR**. Combination of erlotinib and epigallocatechin-3-gallate induces apoptosis of squamous cell carcinoma of the head and neck through posttranslational regulation of Bim and Bcl-2. AACR Annual Meeting, 2014.
 14. Rahman MA, **Amin AR**, Peng XH, Zhang J, Chen ZG and Shin DM. Ribonucleotide reductase subunit M2 plays important role in cisplatin resistance of cancer cells. AACR Annual Meeting, 2014.
 15. Jiang N, Wang D, Hu Z, Rahman MA, Zhang HZ, **Amin AR**, Wang X, Chen Z, Shin DM, Garcia G, MacBeath G, Ma J, Khuri FR, Saba NF and Chen ZG. Combined treatment with HER3 antibody MM-121/SAR 256212 and EGFR antibody cetuximab in pre-clinical models of head and neck cancer, AACR Annual Meeting, 2013.
 16. **Amin AR**, Rahman MA, Wang D, Khuri FR, Fuchs JR, Chen ZG and Shin DM. Potent curcumin analogue FLLL-12 targets protein translational pathways to inhibit EGFR, AKT and Bcl-2: potential role in apoptosis induction, AACR Annual Meeting, 2013.
 17. Rahman MA, **Amin AR**, Nannapaneni N, Hu Z, Kang H, Chen ZG and Shin DM. Role of ribonucleotide reductase subunit M2 in regulation of head and neck and lung cancer undergoing invasion, AACR Annual Meeting, 2013.
 18. **Amin AR**, Rahman MA, Wang D, Khuri FR, Chen ZG and Shin DM. Synergistic apoptosis by combination of natural compound EGCG and resveratrol in head and neck cancer: Potential role for AKT-dependent signaling. AACR Annual Meeting, 2012.

19. Rahman MA, **Amin AR**, Koenig K, Nannapaneni N, Chen ZG and Shin DM. Ribonucleotide reductase subunit M2 regulates Bcl-2 in human cancer: A potential target for cancer therapy. AACR Annual Meeting, 2012.
20. Wang X, Beitler JJ, Hong HW, Lee MJ, Chen Z, Koenig L, **Amin AR**, Chen ZG, Arbiser JL and Shin DM. Honokiol reduces drug resistance by down-regulation of survivin expression in multidrug resistant squamous cell carcinoma of the head and neck. AACR Annual Meeting 2012.
21. **Amin AR**, Rahman MA, Wang D, **Nannapaneni N**, Khuri FR, Chen ZG and Shin DM. Targeting AKT-mediated Pathways with a Combination of Natural Compounds EGCG and Resveratrol in Head and Neck Cancer: Potential for Adjuvant Therapy. 8th International Conference on Head & Neck Cancer, 2012.
22. **Amin AR**, Lee M, Rahman MA, Fuchs JR, Chen ZG and Shin DM. Potent curcumin analogue FLLL-22, but not natural curcumin, targets the DNA damage pathway for apoptosis in lung and head and neck cancer cells. AACR Annual Meeting, 2011.
23. **Amin AR**, Jung KH, Arbiser JL, Chen ZG and Shin DM. Targeting Cell Survival Pathways with the Combination of Honokiol and Resveratrol for Prevention of Head and Neck Cancer. AACR Annual Meeting, 2011.
24. Rahman MA, **Amin AR**, Chen ZG, Davis ME and Shin DM. Ribonucleotide reductase subunit M2 promotes cell invasiveness and motility in lung and head and neck cancer cells. AACR Annual Meeting, 2011.
25. Wang D, **Amin AR**, Peng S, Sanghvi C, Shin DM and Eichler JF. Study of 2, 9-disecbutyl-1, 10-phenanthroline as a novel anticancer agent, AACR Annual Meeting, 2011.
26. **Amin AR**, Wang D, Zhang HZ, Peng S, Koenig L, Brandes JC, Mourad T, Khuri FR, Chen ZG and Shin DM. Highly synergistic anti-tumor efficacy induced by the combination of two natural dietary agents, luteolin and EGCG: Role of p53 phosphorylation, stabilization and translocation. AACR Annual Meeting, 2010.
27. Rahman MA, **Amin AR**, Wang X, Wang D, Davis ME, Zhou B, Yen Y, Chen ZG and Shin DM. Nanoparticle mediated delivery of siRNA targeting RRM2 inhibits tumor growth of head and neck and lung cancers. AACR Annual Meeting, 2010.
28. Wang D, Wang Y, **Amin AR**, Su L, Muller S, Huang D, Nannapaneni N, Koenig K, Chen Z, Pan L, Tighiouart T, Shin DM and Chen ZG. Integrin β 1 contributes to metastasis and prognosis of squamous cell carcinoma of the head and neck (HNSCC). AACR Annual Meeting, 2010.
29. **Amin AR**, Wang D, Khuri FR, Chen ZG and Shin DM. *In vitro* and *in vivo* synergistic anti-tumor efficacy of two naturally available dietary polyphenols EGCG and luteolin. AACR Annual Meeting, 2009.
30. **Amin AR**, Zhang X, Khuri FR, Chen ZG and Shin DM. Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and EGCG: the role of p53-dependent inhibition of nuclear factor- κ B. AACR Annual Meeting, 2009.

31. **Amin AR**, Zhang X, Khuri FR, Chen ZG and Shin DM. Inhibition of erlotinib-induced checkpoint but not apoptotic targets by EGCG: implication for their anti-tumor synergism in squamous cell carcinoma of the head and neck. AACR Annual Meeting, 2008.
32. Shin DM, **Amin AR**, Zhang X, Zhou Chen ZG, and Khuri FR. Effective combination of Green Tea EGCG and EGFR-TKI erlotinib for chemoprevention and therapy in head and neck cancer. 20th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics", 2008.
33. Paul RK, **Amin AR**, Thakur VS and Agarwal ML. p53-dependent generation of reactive oxygen species mediates apoptosis by Luteolin. AACR Annual Meeting, 2007.
34. Thakur VS, **Amin AR**, Paul RK and Agarwal ML. p21-mediated cell cycle arrest predominates and protects colon cancer cells from p53-dependent apoptosis by EGCG. AACR Annual Meeting, 2007.
35. Hastak K, Paul RK, Thakur VS, **Amin AR**, Agarwal S, Jackson MW, Stark GR and Agarwal ML. Continued DNA synthesis under imbalanced nucleotide pools leads to DNA damage and ATR/Chk1-dependent phosphorylation and activation of p53. AACR Annual Meeting, 2007.
36. **Amin AR** and Agarwal ML. Opposing roles for p53 and p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis. AACR Annual Meeting, 2007.
37. **Amin AR**, Thakur VS, Paul RK, Feng GS, Mukhtar H and Agarwal ML. SHP2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG. AACR Annual Meeting, 2007.
38. **Amin AR**, Mukhtar H and Agarwal ML. Identification of tyrosine phosphatase SHP-2 as a negative regulator of p53-independent apoptosis and p53-target gene expression. AACR Annual Meeting, 2006.
39. **Amin AR** and Agarwal ML. p53-dependent activation of Akt signaling in differential cellular growth by Concanavalin A. AACR Annual Meeting, 2006.
40. Hastak K, **Amin AR**, Agarwal MK, Mukhtar H and Agarwal ML. P53 signaling in negative regulation of cellular growth by green tea. 8th International Conference on Nutrition and Cancer, 2005.
41. **Amin AR** and Hamaguchi M. Secretion of MMP-9 by the proinflammatory cytokine IL-1 β : a role for SHPS-1-dependent activation of Akt and Erk signalings. 8th World Congress on Advances in Oncology and 6th International Symposium in Molecular Medicine. 2003.
42. Hamaguchi M and **Amin AR**. MEK1-MAPK and PI3K-AKT signalings are required for MMP-9 secretion by IL-1 β . European Journal of Biochemistry 270. 2003
43. **Amin AR** and Hamaguchi M. A role for SHPS-1-SHP-2 complex formation in IL-1 β and TNF α signalings. Annual Meeting of the Japanese Cancer Association. 2002.
44. **Amin AR**, Machida K, Oshima K and Hamaguchi M. Role of SHPS-1-SHP-2-PLC- γ complex formation in IL-1 β -dependent MAP kinase activation and cell proliferation. 17th Annual Meeting on Oncogenes. 2001.
45. **Amin AR**, Machida K, Senga T, Thant AA, Matsuda S and Hamaguchi M. IL-1 β -mediated activation of PI (3) kinase-Akt pathway. 73rd Annual Meeting of Japanese Biochemical Society, 2000.

